Ex vivo biomarkers: Functional tools to guide targeted drug development and therapy

Expert Review of Molecular Diagnostics

Volumn 9, Issue 8, 2009, Pages 787-794

  Clark, Douglas P ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Biomarker; Drug development; Oncology; Predictive marker; Signal transduction; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CL 1040; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; ON 01910; ON 01910.NA; ON 01913.NA; PROTEIN SERINE THREONINE KINASE INHIBITOR; SORAFENIB; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; XL 019;

ACUTE GRANULOCYTIC LEUKEMIA; ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL PROLIFERATION; CELL VIABILITY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL DECISION MAKING; DRUG DEVELOPMENT; DRUG MEGADOSE; DRUG TARGETING; ENZYME INHIBITION; EX VIVO STUDY; FLOW CYTOMETRY; HEMATOLOGIC MALIGNANCY; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; NONHUMAN; PANCREAS CANCER; PANCREAS CARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR CELL; TUMOR XENOGRAFT; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

DECISION MAKING; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HEMATOLOGIC NEOPLASMS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 70449647025     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.09.62     Document Type: Review

References (44)

1. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118-145 (2007).
2. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
3. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20(3), 719-726 (2002).
4. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17(9), 2639-2648 (1999).
5. Rosell R, Perez-Roca L, Sanchez JJ et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE 4(5), e5133 (2009).
6. Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 26(15), 2442-2449 (2008).
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005). (Pubitemid 41058344)
8. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27(12), 2091-2096 (2009).
9. Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. N. Engl. J. Med. 359(17), 1834-1836 (2008).
10. Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439(7073), 168-174 (2006). (Pubitemid 43083134)
11. Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol. Syst. Biol. 1, 2005.0008 (2005).
12. Uetz P, Stagljar I. The interactome of human EGF/ErbB receptors. Mol. Syst. Biol. 2, 2006 0006 (2006).
13. Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nat. Rev. Cancer 6(9), 735-741 (2006). (Pubitemid 44304232)
14. Gulmann C, Sheehan KM, Kay EW, Liotta LA, Petricoin EF 3rd. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J. Pathol. 208(5), 595-606 (2006).
15. Kwak EL, Clark JW, Chabner B. Targeted agents: the rules of combination. Clin. Cancer Res. 13(18), 5232-5237 (2007).
16. Gal AA. In search of the origins of modern surgical pathology. Adv. Anat. Pathol. 8(1), 1-13 (2001).
17. Gephardt GN, Zarbo RJ. Extraneous tissue in surgical pathology: a College of American Pathologists Q-Probes study of 275 laboratories. Arch. Pathol. Lab. Med. 120(11), 1009-1014 (1996).
18. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am. J. Pathol. 161(6), 1961-1971 (2002).
19. Mazurek GH, LoBue PA, Daley CL et al. Comparison of a whole-blood interferon γ assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 286(14), 1740-1747 (2001).
20. Blumenthal RD, Goldenberg DM. Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Mol. Biotechnol. 35(2), 185-197 (2007).
21. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J. Clin. Oncol. 22(17), 3631-3638 (2004).
22. Rubio-Viqueira B, Jimeno A, Cusatis G et al. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 12(15), 4652-4661 (2006). • Describes ex vivo functional profiling of pancreatic cancer.
23. Irish JM, Kotecha N, Nolan GP. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat. Rev. Cancer 6(2), 146-155 (2006). •• Comprehensive review of ex vivo signaling profiling of tumor cells by a leading laboratory in the field.
24. Schulz KR, Danna EA, Krutzik PO, Nolan GP. Single-cell phospho-protein analysis by flow cytometry. Curr. Protoc. Immunol. 8, 8.17 (2007).
25. Irish JM, Hovland R, Krutzik PO et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118(2), 217-228 (2004). • Describes ex vivo functional profiling of acute myeloid leukemia (AML).
26. Irish JM, Anensen N, Hovland R et al. Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood 109(6), 2589-2596 (2007). • Describes ex vivo functional profiling of AML.
27. Kotecha N, Flores NJ, Irish JM et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 14(4), 335-343 (2008). • Describes ex vivo functional profiling of leukemias.
28. Irish JM, Czerwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 108(9), 3135-3142 (2006). • Describes ex vivo functional profiling of follicular lymphoma.
29. Ricciardi MR, McQueen T, Chism D et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia 19(9), 1543-1549 (2005). • Describes ex vivo functional profiling of AML.
30. Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in Phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin. Cytom. 70(3), 107-114 (2006). • Describes ex vivo functional profiling of AML.
31. Centeno BA, Enkemann SA, Coppola D, Huntsman S, Bloom G, Yeatman TJ. Classification of human tumors using gene expression profiles obtained after microarray analysis of fine-needle aspiration biopsy samples. Cancer 105(2), 101-109 (2005). (Pubitemid 40604944)
32. Symmans WF, Ayers M, Clark EA et al. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97(12), 2960-2971 (2003). (Pubitemid 36676249)
33. Jimeno A, Kulesza P, Kincaid E et al. C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res. 66(4), 2385-2390 (2006). • Describes ex vivo functional profiling of cholangiocarcinoma.
34. Rubio-Viqueira B, Mezzadra H, Nielsen ME et al. Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. Mol. Cancer Ther. 6(2), 515-523 (2007). • Describes ex vivo functional profiling of pancreatic cancer.
35. Jimeno A, Chan A, Cusatis G et al. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene 28(4), 610-618 (2009). • Describes ex vivo functional profiling of pancreatic cancer.
36. Srivastava S, Gray JW, Reid BJ, Grad O, Greenwood A, Hawk ET. Translational Research Working Group developmental pathway for biospecimen-based assessment modalities. Clin. Cancer Res. 14(18), 5672-5677 (2008).
37. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin. Cancer Res. 14(19), 5967-5976 (2008).
38. Glassman RH, Ratain MJ. Biomarkers in early cancer drug development: limited utility. Clin. Pharmacol. Ther. 85(2), 134-135 (2009).
39. Allison M. Is personalized medicine finally arriving? Nat. Biotechnol. 26(5), 509-517 (2008). (Pubitemid 351668034)
40. Carden CP, Banerji U, Kaye SB, Workman P, de Bono JS. From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin. Pharmacol. Ther. 85(2), 131-133 (2009).
41. Davis JC, Furstenthal L, Desai AA et al. The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat. Rev. Drug Discov. 8(4), 279-286 (2009).
42. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
43. National Cancer Institute Office of Biorepositories and Biospecimen Research http://biospecimens.cancer.gov
44. BioMarker Strategies www.biomarkerstrategies.com